Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid
复制标题
利用唾液中的治疗药物监测来优化一线结核病药物的剂量：对利福平可行，但对异烟肼不可行
DOI：
10.1183/13993003.00803-2020
复制
发表时间：
2020
影响因子：
24.3
通讯作者：
J. Alffenaar
中科院分区：
文献类型：
--
作者：
Simone H. J. van den Elsen;O. Akkerman;Mireille A. Wessels;Erwin M. Jongedijk;S. Ghimire;T. S. van der Werf;M. Bolhuis;D. Touw;J. Alffenaar
结核病（TB）在全球范围内的持续负担令人担忧。2018年，估计有1000万人患上结核病，145万感染者死亡[1]。 抗药性的增加是一个重要的关切点。耐药可通过不适当的药物管理、不依从和药物暴露不足获得[2，3]。由于个体间药代动力学变异性较大，最后一种情况经常出现在一线结核病药物利福平和异烟肼中[3]。治疗药物监测（TDM）可用于验证药物暴露，并在需要时调整个体药物剂量[4]。使用唾液样本进行治疗药物监测对于利福平是可行的，尽管渗透率低，但对于异烟肼是不可行的，因为异烟肼显示出令人费解的高度可变的唾液/血清浓度比。https://bit.ly/2yAS2Jc
The persisting worldwide burden of tuberculosis (TB) is worrisome. In 2018, an estimated 10 million individuals developed TB and 1.45 million infected individuals died [1]. The increase in drug resistance is an important point of concern. Resistance can be acquired by inappropriate drug management, noncompliance and insufficient drug exposure [2, 3]. The last is frequently described for the first-line TB drugs rifampicin and isoniazid due to large interindividual pharmacokinetic variability [3]. Therapeutic drug monitoring (TDM) can be used to verify drug exposure and adjust individual drug dosages if needed [4]. Therapeutic drug monitoring using saliva samples is feasible for rifampicin, despite low penetration, but is not feasible for isoniazid, which showed inexplicable highly variable saliva/serum concentration ratios https://bit.ly/2yAS2Jc
影响因子：
6.4
作者：
Srivastava, Shashikant;Pasipanodya, Jotam G.;Gumbo, Tawanda
通讯作者：
Gumbo, Tawanda
影响因子：
6.4
作者：
Pasipanodya, Jotam G.;McIlleron, Helen;Gumbo, Tawanda
通讯作者：
Gumbo, Tawanda